PremiumCompany AnnouncementsCellectar Biosciences Earnings Call: Mixed Outlook Amid Successes and Challenges Cellectar Biosciences reports FY24 EPS ($1.40), consensus ($1.57) Cellectar Biosciences sees cash runway into 4Q25 PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Cellectar Biosciences Strategic Shift and Workforce Reduction Cellectar Biosciences downgraded to Perform from Outperform at Oppenheimer PremiumThe FlyCellectar Biosciences price target lowered to $12 from $14 at Oppenheimer Cellectar Biosciences Reports Q3 2024 Financial Results Cellectar Biosciences reports Q3 EPS (40c), consensus (37c) 
